The Administration's Theory of Healthcare Reform
The administration's stated rationale rests on three related arguments: that federal health programs have grown fiscally unsustainable, that excessive regulation raises costs and crowds out market competition, and that many current beneficiaries — particularly working-age, able-bodied adults on Medicaid — receive benefits for which they bear no reciprocal obligation. From this premise, the administration argues that tighter eligibility verification, work requirements, reduced subsidies, and market-oriented pricing reforms will produce a leaner, more honest system without harming the truly needy.
On drug pricing, the administration has pressed a different kind of market argument: that American consumers subsidize lower drug prices elsewhere and that forcing pharmaceutical companies to align U.S. prices with those paid in peer nations corrects a fundamental market distortion. This reasoning leads the administration toward more direct government intervention on prices — a posture that sits in some tension with its general preference for deregulation — though the administration frames it as correcting a market failure rather than imposing price controls.
Coverage, Eligibility, and Federal Spending
On July 4, 2025, President Trump signed the One Big Beautiful Bill Act into law, which includes nearly $1 trillion in cuts to Medicaid to help offset the cost of the legislation's tax reductions. CBO estimated that changes in the final legislation would cut roughly $1.1 trillion in health-care spending over the next decade, with more than $1 trillion coming from Medicaid, the joint federal-state program for disabled and low-income Americans.
The law's Medicaid provisions are phased in over several years. Work requirements, which account for many of the nearly 12 million people projected to lose coverage under the bill, generally will not take effect until 2027, and able-bodied recipients ages 19 to 64 would not actually be dropped from program rolls for failure to meet the required 80 hours per month until after November 2026. Effective December 2026, the Act eliminates a five-percent increase in federal matching funds that had incentivized states to adopt Medicaid expansion, and it requires states to conduct eligibility redeterminations for expansion enrollees every six months rather than every twelve.
On the ACA marketplace side, the administration chose not to extend the enhanced premium subsidies that had been in place since 2021. The enhanced premium tax credits had driven ACA enrollment to record highs, but when they expired at the end of 2025, premium payments rose sharply for many enrollees, particularly those with incomes above 400 percent of the federal poverty level. KFF researchers estimated that marketplace enrollment could fall from 22.3 million in 2025 to 17.5 million in 2026 — a drop of nearly five million people. Average monthly premium payments rose from $113 to $178, a 58 percent increase on average, while deductibles surged by roughly 37 percent, or about $1,027 per person.
Prices, Competition, and the Role of Government
On May 12, 2025, President Trump signed an executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," directing the administration to take numerous actions to bring American drug prices in line with those paid by similar nations. U.S. prescription drug prices are two to three times higher on average than those in other developed nations, and the administration has cited this gap as the core justification for the policy. In July 2025, Trump sent letters to leading pharmaceutical manufacturers outlining steps they must take to bring down prices, and since September 2025 the White House has announced deals with several major manufacturers.
The executive order directs HHS to implement most-favored-nation pricing through rulemaking if manufacturers do not voluntarily lower prices, with HHS potentially using the Centers for Medicare and Medicaid Innovation as a vehicle — though reimbursement mechanisms for federal programs are established by statute, raising legal questions about the administration's ultimate authority. Experts have also questioned whether the administration can cut prices significantly, as it remains unclear which specific drugs and nations will be targeted.
On site-neutral payments, CMS issued a final rule that sets the amount Medicare reimburses hospitals for certain services to reflect the reimbursement for similar care outside a hospital setting, which according to CMS will save Medicare $220 million in 2026. The One Big Beautiful Bill Act also carves out orphan drugs — medications for rare diseases — from Medicare's drug price negotiation process, limiting the government's ability to control costs for some of the most expensive medications.
Public Health, Medical Research, and Agency Capacity
The administration's budget proposals included a $3.588 billion cut to the Centers for Disease Control, a $17.965 billion cut to NIH, and a $674 million cut to CMS, among other reductions. Whether Congress ultimately appropriated at those levels remained under negotiation, but the proposals signaled the administration's intent to substantially reduce the federal public health and research infrastructure. The administration framed these reductions as eliminating waste and bureaucratic redundancy, consistent with the broader DOGE mandate to shrink the federal workforce.
The FDA has also been drawn into the drug pricing agenda. The most-favored-nation executive order directed the FDA to consider modifying or revoking drug approvals for drugs that are ineffective, unsafe, or improperly marketed, and to consider case-by-case drug importation waivers — a leverage mechanism that critics have argued conflates safety regulation with pricing negotiations. CMS separately decided against expanding Medicare Advantage and Part D coverage to anti-obesity medications in its 2026 rate announcement, a decision that drew criticism from patient advocates and obesity medicine specialists.
Effects on Patients, Providers, States, and Insurers
States face the most immediate fiscal pressure. The legislation's $930 billion cut to federal Medicaid funding will likely force states to make corresponding cuts to their programs or pick up a greater share of obligations. A key source of Medicaid savings involves a provision capping and gradually reducing the provider taxes that states impose on hospitals, health plans, and other medical providers, taxes that are an important way states fund their portion of Medicaid costs — meaning states are likely to cut provider payments in response.
For hospitals, especially rural and safety-net facilities, the combination of Medicaid funding reductions and site-neutral payment rules poses a compounding challenge. CMS's site-neutral rule may decrease reimbursement to some sites of service by as much as 60 percent, which likely poses a particular financial challenge for hospitals with limited financial reserves. Insurers operating in the ACA marketplace, meanwhile, face an enrollment pool that is smaller and potentially sicker, as healthier enrollees opt out when premiums rise — a dynamic that could in turn push premiums higher still.
For Medicare beneficiaries, the administration's move to end subsidies for Medicare drug plans may push patients away from traditional Medicare and toward Medicare Advantage plans, which may have lower premiums but offer more limited networks of providers and hospitals. If Congress takes no additional action, automatic spending cuts triggered by the legislation could reduce Medicare funding by approximately $500 billion between 2026 and 2034.
The administration's regulatory changes to marketplace enrollment rules have faced sustained legal challenges. The Trump administration issued a program integrity rule making substantial changes to marketplace enrollment processes and eligibility for premium tax credits, but many of those changes were temporarily halted by a federal court in Maryland. In issuing the temporary stay, U.S. District Judge Brendan Hurson questioned whether the government had adequately responded to questions about the accuracy of data it used in citing widespread fraud.
The Test of Affordability and Access
The administration's central promise — that these reforms will reduce costs and intrusive government while preserving care for those who genuinely need it — faces a mixed evidentiary record at this stage. On drug pricing, the executive order represents a meaningful departure from prior Republican orthodoxy and has produced some negotiated commitments from manufacturers; whether those commitments translate into durable price reductions for patients remains to be established. The legal foundation for imposing most-favored-nation pricing through rulemaking is genuinely contested.
On coverage, the evidence available through mid-2026 suggests that the reforms have reduced the number of insured Americans rather than preserved it. The administration itself projected that its 2027 proposed marketplace rule changes would reduce enrollment by 1.2 to 2 million people — losses on top of 2026 changes already expected to leave 7.5 million people uninsured. The work-requirement and eligibility redetermination provisions of the One Big Beautiful Bill Act have not yet fully taken effect; their actual impact on coverage will become clearer in 2027 and beyond. People covered through ACA exchanges are experiencing changes more swiftly, as the bill did not extend the Biden-era enhanced premium subsidies, which expired on January 1, 2026.
What can be said with reasonable confidence is that federal health spending has been constrained, that pharmaceutical manufacturers have faced more explicit government pricing pressure than at any point in recent memory, and that enrollment in both Medicaid and ACA marketplace plans has declined. Whether the patients who have lost or may lose coverage are primarily those the administration regards as ineligible or peripheral to the program's mission — or whether coverage losses extend to the populations the administration explicitly sought to protect — is the core question that the next several years of implementation data will answer.
Sources
Axios, "Trump bill's health effects won't be felt until after midterms" (Jul. 2025)
CNBC, "Trump most favored nations drug price executive order: What to know" (May 2025)
Congress.gov / CRS, "Most-Favored-Nation Prescription Drug Pricing Executive Order: Legal Issues."
Georgetown Center on Health Insurance Reforms, "What to Expect for Open Enrollment, 2026 Edition."
KFF, "8 Things to Watch for the 2026 ACA Open Enrollment Period" (Oct. 2025)
Further Reading and Listening
Progress Lost — The Unraveling of Medicaid and the Affordable Care Act
New England Journal of Medicine, July 30, 2025
Health-policy scholar Jonathan Oberlander argues that the 2025 budget reconciliation act represents the largest rollback of health insurance coverage in U.S. history, making it harder to qualify for and stay enrolled in both Medicaid and subsidized ACA coverage. An essential analytical framing piece for understanding the scale of what the One Big Beautiful Bill Act set in motion.
State-Level Impacts of Key Medicaid Provisions in the One Big Beautiful Bill Act
RAND Corporation, 2026
This updated RAND research report builds state-by-state estimates of Medicaid budget impact and enrollment changes through 2034, finding that state Medicaid funds will fall by roughly $664 billion and that expansion states relying heavily on provider taxes face the steepest losses. The state-level granularity makes it an indispensable reference for tracking how the law's effects will be distributed across the country.
Tracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements
KFF, Ongoing (last updated August 2026)
KFF's continuously updated interactive tracker monitors how all 44 states subject to the new federal work requirements are preparing for the January 2027 deadline, including which states are moving early and what federal guidance has said about contested definitions like "medical frailty." It is the single most comprehensive live resource for following implementation on the ground.
Survey Offers Early Look at States' Differing Approaches to Implementing Medicaid Work Requirements
KFF, May 1, 2026
Drawing on a survey of state Medicaid officials and focus groups in eight states, this KFF report finds that states face significant time, cost, and guidance uncertainties as they prepare for work requirements, with seven states planning more restrictive verification approaches or early implementation. It offers the most detailed early look at how implementation choices will translate into coverage consequences before the 2027 deadline.
Developments in Prescription Drug Pricing under the Second Trump Administration
KFF, April 13, 2026
This KFF forum event page summarizes the administration's overlapping drug-pricing strategies — Most Favored Nation agreements, tariff leverage over branded manufacturers, and the planned TrumpRx direct-purchase website — and explains how voluntary MFN deals with pharmaceutical companies are structured as tariff-relief exchanges. It provides a unified map of the administration's multi-track approach to lowering drug costs.
Drug Pricing in the Era of Trump 2.0
Georgetown University Center on Health Insurance Reforms – Medicare Policy Initiative, Ongoing
This tracker from Georgetown's Medicare Policy Initiative follows each successive round of IRA Medicare drug price negotiations under the Trump administration, noting that the November 2025 announcement of second-round negotiated prices for 15 drugs — including Ozempic and Wegovy — is projected to save Medicare $12 billion annually beginning in 2027. It also documents how the One Big Beautiful Bill Act's expanded orphan-drug exclusion will affect future negotiation rounds.
Will pharmaceutical tariffs achieve their goals?
Brookings Institution, October 1, 2025
This Brookings analysis examines the two stated goals of Trump's pharmaceutical tariff agenda — onshoring drug production and securing supply chains — against the structural realities of the generic and branded drug markets, warning that tariffs could produce drug shortages and price increases rather than domestic manufacturing gains. It remains the foundational policy-economics piece for assessing the tariff strategy's feasibility.
Why ACA enrollment has fallen by millions
CNBC, July 3, 2026
This piece documents the roughly 3 million–person decline in ACA marketplace enrollment between the end of 2025 and February 2026 — the largest single-year drop since the marketplaces were established — and examines the contested debate between the administration's fraud-and-abuse explanation and health-policy experts who point to the lapse of enhanced premium subsidies as the primary driver. The political framing around the midterm cycle adds important context.
ACA Exchange Enrollment in 2026
U.S. Department of Health and Human Services – ASPE, June 26, 2026
This official HHS report presents the administration's primary-source case that the enrollment drop to 19.2 million reflects the removal of fraud, waste, and abuse — including an estimated 2.6 million improper enrollments — rather than subsidy-driven coverage loss. Reading it alongside independent analyses gives a full picture of the disputed evidence on ACA enrollment trends.
The ACA health coverage subsidy lapse hit 22 million people. Here are some of their stories
CNBC, February 24, 2026
This reported piece puts human texture on the subsidy expiration's impact, including cases of out-of-pocket premiums tripling in 2026 for households in GOP-won states — where 88 percent of ACA enrollment growth since 2020 had occurred. It also provides the political context of why extending subsidies stalled even as Republicans acknowledged their impact in red America.
The FDA Is Officially Codifying DOGE-Era Changes
NOTUS, July 28, 2026
This report reveals that the FDA is formalizing its post-DOGE restructuring under a "Simple Reform" model taking effect October 1, consolidating administrative functions across all nine centers into a shared-services office — a permanent organizational consequence of the roughly 3,500-employee workforce reduction in 2025. It is the most current account of how DOGE's cuts are being institutionalized rather than reversed.
Trump's generic drug tariffs will test his pharma strategy
Axios, July 28, 2026
This analysis explains why the administration's turn toward 100–200 percent tariffs on generic drugs poses a distinct and more dangerous economic challenge than tariffs on branded medicines: generic manufacturers operate on thin margins and may simply exit the U.S. market rather than invest in domestic production, risking drug shortages. Brookings senior fellow Marta Wosinska and other experts explain why the logic that worked for branded-drug MFN deals does not translate to the generics sector.
All comments and responses are publicly visible.
To comment, you must register with a working email address.
Because the site is updated regularly, if you are commenting on a specific passage, consider copying the relevant text into your comment so readers can tell exactly what you are referring to.
We especially welcome proposed topics, corrections, and suggestions.
Please address the subject matter rather than other commenters personally. Spam, abusive material, substantially off-topic comments, and other inappropriate comments may be removed.